Cargando…

Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women

OBJECTIVE: To evaluate the efficacy and side effects of Oxybutinin in comparison to tolterodine in treatment of overactive bladder (OAB) with detrussor overactivity (DOA) in Iranian women. MATERIALS AND METHODS: One hundred Iranian old women with clinical symptoms of OAB who show IDO in the filling...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aziminekoo, Elham, Ghanbari, Zinat, Hashemi, Shahrzad, Nemati, Maryam, Haghollahi, Fedyeh, Shokuhi, Nasim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064768/ https://www.ncbi.nlm.nih.gov/pubmed/24971138

Ejemplares similares

Effect of Urinary Incontinence on Quality of Life among Iranian Women
por: Mallah, Fatemeh, et al.
Publicado: (2014)

Efficacy of tolterodine in children with overactive bladder
por: Koç, Başak, et al.
Publicado: (2020)

Transdermal oxybutynin in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2006)

Update on tolterodine extended-release for treatment of overactive bladder
por: Omotosho, Tola, et al.
Publicado: (2010)

Oxybutynin topical gel in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2010)

Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder
por: Rajabalaya, Rajan, et al.
Publicado: (2016)

Development of oxybutynin chloride topical gel for overactive bladder
por: Lucente, Vincent R, et al.
Publicado: (2011)

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
por: Ulahannan, Danny, et al.
Publicado: (2009)

Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin
por: Gamble, Tondalaya, et al.
Publicado: (2008)

Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions
por: Angelico, Patrizia, et al.
Publicado: (2005)

Oxybutynin extended release for the management of overactive bladder: a clinical review
por: Arisco, AM, et al.
Publicado: (2009)

Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review
por: Vozmediano-Chicharro, Raúl, et al.
Publicado: (2020)

Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain
por: Crespo, Carlos, et al.
Publicado: (2018)

Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome
por: Shabir, Habiba, et al.
Publicado: (2021)

The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial
por: Xiao, Dong-dong, et al.
Publicado: (2016)

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function
por: Zachariou, Athanasios, et al.
Publicado: (2017)

Effects of Bladder Training and/or Tolterodine in Female Patients with Overactive Bladder Syndrome: A Prospective, Randomized Study
por: Song, Cheryn, et al.
Publicado: (2006)

Comparison Pregnancy Outcomes Between Minimal Stimulation Protocol and Conventional GnRH Antagonist Protocols in Poor Ovarian Responders
por: Pilehvari, Shamim, et al.
Publicado: (2016)

Comparison of combined treatment with desmopressin plus oxybutynin and desmopressin plus tolterodine in treatment of children with primary nocturnal enuresis
por: Azarfar, Anoush, et al.
Publicado: (2015)

Comparison of Biomedical Variables in PCOS Patients with Normal Iranian Women
por: Bagheri, Maryam, et al.
Publicado: (2015)

Rate of urinary tract infection after urodynamic study in pelvic floor clinic
por: Ghanbari, Zinat, et al.
Publicado: (2020)

Dissimilar Effects of Tolterodine on Detrusor Overactivity in Awake Rats with Chemical Cystitis and Partial Bladder Outlet Obstruction
por: Jin, Long-Hu, et al.
Publicado: (2011)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?
por: Vozmediano-Chicharro, Raúl, et al.
Publicado: (2018)

Effect of Soy Milk Consumption on Quality of Life in Iranian Postmenopausal Women
por: Nourozi, Mansoreh, et al.
Publicado: (2015)

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Comparison of micro-radiofrequency therapy and tolterodine for the treatment of newly diagnosed overactive bladder: A retrospective cohort study
por: Tang, Min, et al.
Publicado: (2023)

Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats
por: Sun, Peng, et al.
Publicado: (2022)

Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions
por: Staskin, D R, et al.
Publicado: (2008)

Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder
por: Wagg, Adrian
Publicado: (2012)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Female Sexual Function During the Menopausal Transition in a Group of Iranian Women
por: Eftekhar, Tahereh, et al.
Publicado: (2016)

AB078. Disease correlation and effects of pelvic floor muscle training on tolterodine based treatment for female primary overactive bladder syndrome
por: Huang, Xiao, et al.
Publicado: (2016)

The effect of vitamin D supplementation on the size of uterine leiomyoma in women with vitamin D deficiency
por: Hajhashemi, Maryam, et al.
Publicado: (2019)

Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo
por: Van Kerrebroeck, Philip EV, et al.
Publicado: (2009)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
por: Herschorn, Sender, et al.
Publicado: (2018)

Clinical outcomes in patients with advanced pelvic prolapse who underwent LeFort surgery or pessary placement- A prospective cohort study
por: Gholamian, Elham, et al.
Publicado: (2022)

207: TRANSLATION AND PSYCHOMETRIC PROPERTIES OF IRANIAN VERSION OF OVERACTIVE BLADDER SYNDROME SCORE (OABSS)
por: Hakimi, Sevil, et al.
Publicado: (2017)

Comparative Study of the Effect of Vaginal use of Primrose Oil with Misoprostol on Cervical Preparation of Prim Gravid Women: A Double-blind Clinical Trial
por: Shahraki, Azar Danesh, et al.
Publicado: (2023)

Comparison of highly purified urinary versus recombinant FSH: Effect on ART outcomes in polycystic ovary syndrome
por: Sohrabvand, Farnaz, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_brmbd2jpgp0eibvke8hhgtee6t